TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35671392

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT) without preceding enzyme replacement therapy (ERT)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT) preceded by enzyme replacement therapy (ERT-HCT)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Gene therapy (GT) preceded by enzyme replacement therapy (ERT-GT)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT) at <3.5 months of age
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT) at ≥3.5 months of age
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Active infection at the time of HCT
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: No active infection at the time of HCT
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Matched sibling and matched family donors (MSD/MFD)
Number of subjects: 131

Group type: COMPARATOR
Intervention: HCT using a variety of transplant approaches and ERT-GT
Number of subjects: 131
Study: 35671402

Group type: EXPERIMENTAL
Intervention: Toolkit provision including a guide, smartphone app, and video for administering walk tests.
Number of subjects: 54
Study: 35671611

Group type: EXPERIMENTAL
Intervention: Q-NRG® in canopy mode
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Q-NRG® in face mask mode
Number of subjects: 85
Study: 35672037

Group type: EXPERIMENTAL
Intervention: Shared decision making during the COVID-19 pandemic
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Patient treatment choices
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Clinician experiences during the pandemic
Number of subjects: 76
Study: 35672071

Group type: EXPERIMENTAL
Intervention: Patients with TB
Number of subjects: 450

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 450
Study: 35672139

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 13454

Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilation (NIV)
Number of subjects: 13454

Group type: COMPARATOR
Intervention: High-Flow Nasal Cannula (HFNC) or Noninvasive Ventilation (NIV)
Number of subjects: 13454
Study: 35672221

Group type: EXPERIMENTAL
Intervention: EXIME® prosthesis
Number of subjects: 15

Group type: COMPARATOR
Intervention: Self-catheterization (control group, not explicitly detailed in the abstract)
Number of subjects: 15
Study: 35672552

Group type: EXPERIMENTAL
Intervention: TDF/FTC (PrEP) initiated for participants meeting clinical criteria, dispensed through eHealth.
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: TDF/FTC (PrEP)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Community outreach model via eHealth for PrEP delivery
Number of subjects: 105
Study: 35672675

Group type: EXPERIMENTAL
Intervention: GCS-certified pancreatic cancer centers
Number of subjects: 45318

Group type: COMPARATOR
Intervention: Non-certified hospitals
Number of subjects: 45318
Study: 35672677

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 0
Study: 35672688

Group type: EXPERIMENTAL
Intervention: NEIVATECH virtual reality system (group A) - 18 half-hour in-office therapy sessions for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional patching (group B) - 2 hours of patching per day at home for 3 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NEIVATECH virtual reality system (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional patching (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NEIVATECH virtual reality system (group A) and Conventional patching (group B)
Number of subjects: 60
Study: 35672754

Group type: EXPERIMENTAL
Intervention: Surgical treatment after Monteggia injury
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Subgroup A (ulnar fracture site < 7 cm)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Patients with accompanying injury of the coronoid process
Number of subjects: 35
Study: 35672758

Group type: EXPERIMENTAL
Intervention: Vacuum bottle plus non-tunneled catheter drainage
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 52
Study: 35672860

Group type: EXPERIMENTAL
Intervention: Early intubation (within first 8 hours after vasopressor start)
Number of subjects: 735

Group type: COMPARATOR
Intervention: Unexposed (non-early intubated subjects)
Number of subjects: 735
Study: 35672923

Group type: EXPERIMENTAL
Intervention: Cladribine tablets (dosage and duration not available)
Number of subjects: 0
Study: 35673512

Group type: EXPERIMENTAL
Intervention: Postprandial glucose (evening-time)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) profiling
Number of subjects: 32
Study: 35674086

Group type: EXPERIMENTAL
Intervention: AQP4-IgG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MOG-IgG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GFAP, GRP78 and other novel targets
Number of subjects: 0
Study: 35674343

Group type: EXPERIMENTAL
Intervention: Survivors of childhood cancer
Number of subjects: 571

Group type: COMPARATOR
Intervention: Matched sample from the National Health and Nutrition Examination Survey
Number of subjects: 571
Study: 35674351

Group type: EXPERIMENTAL
Intervention: Ultrasound for quantification of hepatic steatosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRI Proton Density Fat Fraction as reference standard
Number of subjects: 0
Study: 35674389

Group type: EXPERIMENTAL
Intervention: CSCs frequency in locally advanced-stage patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: RG expression in CSCs
Number of subjects: 22

Group type: COMPARATOR
Intervention: RG expression in cancer cells
Number of subjects: 22

Group type: COMPARATOR
Intervention: CSCs frequency in early-stage patients
Number of subjects: 22
Study: 35674480

Group type: EXPERIMENTAL
Intervention: Lenvatinib (dosage not specified, administered daily)
Number of subjects: 21
Study: 35674661

Group type: EXPERIMENTAL
Intervention: Tafasitamab plus Lenalidomide
Number of subjects: 3454
Study: 35674698

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 113
Study: 35674880

Group type: EXPERIMENTAL
Intervention: Tirzepatide (5-mg subcutaneous dose)
Number of subjects: 32
Study: 35675370

Group type: EXPERIMENTAL
Intervention: BNT162b2 (mRNA vaccine)
Number of subjects: 315
Study: 35675590

Group type: EXPERIMENTAL
Intervention: Ponatinib (30 mg/d) with standard induction and consolidation chemotherapy followed by allogeneic hematopoietic stem cell transplant (alloHSCT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ponatinib with chemotherapy followed by alloHSCT
Number of subjects: 30
Study: 35675593

Group type: EXPERIMENTAL
Intervention: Transvaginal mesh repair (TVM)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Native tissue repair (NTR)
Number of subjects: 710
Study: 35675655

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35675673

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35675911

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35676012

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer drug-eluting stents (BP-DES)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Durable polymer drug-eluting stents (DP-DES)
Number of subjects: 8
Study: 35676013

Group type: EXPERIMENTAL
Intervention: Use of expressed human milk at 2 weeks postpartum
Number of subjects: 315
Study: 35676017

Group type: EXPERIMENTAL
Intervention: Multivariate model derived from high dimensional data set including epidemiological, psychometric, quantitative sensory, brain imaging and biological information
Number of subjects: 0
Study: 35676062

Group type: EXPERIMENTAL
Intervention: Cetuximab and nivolumab combination therapy
Number of subjects: 41
Study: 35676068

Group type: EXPERIMENTAL
Intervention: CURB (combined use of radiofrequency ablation and balloon dilation)
Number of subjects: 19
Study: 35676666

Group type: EXPERIMENTAL
Intervention: Supported Osteoarthritis Self-Management Programme (SOASP)
Number of subjects: 143
Study: 35676705

Group type: EXPERIMENTAL
Intervention: ClearSight system (CSCO)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Pulmonary artery catheter bolus thermodilution (TDCO)
Number of subjects: 125
Study: 35676708

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 387

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 387
Study: 35676898

Group type: EXPERIMENTAL
Intervention: FASTER tool
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150
Study: 35677040

Group type: EXPERIMENTAL
Intervention: Antiviral treatment during pregnancy
Number of subjects: 124

Group type: COMPARATOR
Intervention: No antiviral treatment during pregnancy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Healthy non-pregnant women
Number of subjects: 124
Study: 35677073

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 60
Study: 35677318

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m²
Number of subjects: 0
Study: 35677551

Group type: EXPERIMENTAL
Intervention: Very Low-Carbohydrate High-Fat (VLCHF) diet
Number of subjects: 91

Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 91
Study: 35677553

Group type: EXPERIMENTAL
Intervention: Digital healthcare intervention (DHI) designed to prevent post-transplant weight gain, accessed for 12 weeks.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (UC) group received standard dietary and physical activity advice.
Number of subjects: 20
Study: 35677674

Group type: EXPERIMENTAL
Intervention: PrAISED - promoting activity, independence, and stability in early dementia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 35677684

Group type: EXPERIMENTAL
Intervention: Echocardiography guidance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoroscopy guidance
Number of subjects: 60
Study: 35677691

Group type: EXPERIMENTAL
Intervention: CCTA-derived high-risk plaque characteristics (HRPCs)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: CCTA-derived hemodynamic parameters
Number of subjects: 158

Group type: COMPARATOR
Intervention: Clinical risk factors
Number of subjects: 158
Study: 35677980

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients with CVT
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: First 5 months of 2021
Number of subjects: 2313

Group type: COMPARATOR
Intervention: First 5 months of 2020
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Vaccine-induced immune thrombotic thrombocytopenia (VITT) cases in the first 5 months of 2021
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Overall CVT hospitalization volume during the 1st year of the COVID-19 pandemic
Number of subjects: 2313
Study: 35678128

Group type: EXPERIMENTAL
Intervention: Centralized, pharmacy-led penicillin allergy evaluation and single-dose oral challenge
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Surveys distributed to health care personnel
Number of subjects: 23
Study: 35678188

Group type: EXPERIMENTAL
Intervention: Higher level of perceived social support
Number of subjects: 153

Group type: COMPARATOR
Intervention: Lower level of perceived social support
Number of subjects: 153
Study: 35678233

Group type: EXPERIMENTAL
Intervention: Mocetinostat 70-mg with nivolumab and ipilimumab
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mocetinostat 50-mg with nivolumab and ipilimumab
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mocetinostat (both doses)
Number of subjects: 10
Study: 35678263

Group type: EXPERIMENTAL
Intervention: 24-hour fasting
Number of subjects: 47
Study: 35678724

Group type: EXPERIMENTAL
Intervention: Omnipod 5 Automated Insulin Delivery System
Number of subjects: 80
Study: 35678881

Group type: EXPERIMENTAL
Intervention: Diabetes (yes)
Number of subjects: 674

Group type: COMPARATOR
Intervention: No diabetes (no)
Number of subjects: 674
Study: 35679002

Group type: EXPERIMENTAL
Intervention: Male
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Course of diabetes >60 months
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Hyperuricemia
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Massive albuminuria
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Atherosclerosis
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Blood deficiency syndrome
Number of subjects: 492
Study: 35679119

Group type: EXPERIMENTAL
Intervention: Wearable RPM device with early warning scores calculated every 5 minutes (NEWS, ABCNO, wish list score)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Wearable RPM device with early warning scores calculated every 5 minutes (ABCNO score)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Wearable RPM device with early warning scores calculated every 5 minutes (wish list scoring criteria)
Number of subjects: 217
Study: 35679476

Group type: EXPERIMENTAL
Intervention: axi-cel (autologous anti-CD19 chimeric antigen receptor T-cell therapy)
Number of subjects: 171

Group type: COMPARATOR
Intervention: SCHOLAR-5 (external control)
Number of subjects: 171
Study: 35679614

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness assessment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fat oxidation measurement during exercise
Number of subjects: 45
Study: 35679700

Group type: EXPERIMENTAL
Intervention: Radiomics features model (R)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Clinical factors model (C)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Combined parameters model (R + C)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: SVM(R + C)
Number of subjects: 154
Study: 35679775

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory polygraphy findings (min SaO₂, T90, CAI/h)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Respiratory event index (REI) at least 30/h
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Demographic and clinical factors (male gender, older age, diabetes, mRS, GCS, CAI/h)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Peripheral arterial disease (PAD) and NIHSS score
Number of subjects: 204
Study: 35679785

Group type: EXPERIMENTAL
Intervention: Pavlovian fear learning task during functional magnetic resonance imaging
Number of subjects: 282
Study: 35679962

Group type: EXPERIMENTAL
Intervention: Elevated ERN and CRN amplitudes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lab-based neural measures (ERN and CRN)
Number of subjects: 100
Study: 35680043

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W for 35 cycles or until disease progression or unacceptable toxicity
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 351
Study: 35680172

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 15725

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 15725

Group type: EXPERIMENTAL
Intervention: Hispanic patients
Number of subjects: 15725
Study: 35680182

Group type: EXPERIMENTAL
Intervention: Women with previous preeclampsia
Number of subjects: 1417

Group type: COMPARATOR
Intervention: Age- and parity-matched women from the general population
Number of subjects: 1417
Study: 35680192

Group type: EXPERIMENTAL
Intervention: Balloon-expandable TAVR using SAPIEN 3 valve with commissural misalignment (CMA)
Number of subjects: 324
Study: 35680213

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography-derived fractional flow reserve (FFR)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: FFR
Number of subjects: 260
Study: 35680387

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) doses of <5 mg prednisone equivalent per day
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) doses of ≥5 mg/day
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) doses of exactly 5 mg/day
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) doses of >7.5 mg/day in rheumatoid arthritis (RA) patients
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) doses of ≤5 mg/day
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) doses of >7.5 mg/day in RA patients with moderate to high disease activity
Number of subjects: 1066
Study: 35681157

Group type: EXPERIMENTAL
Intervention: INTERCARE model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 35681574

Group type: EXPERIMENTAL
Intervention: Neoadjuvant−adjuvant pertuzumab−trastuzumab-based therapy (Cohort A: dose-dense doxorubicin and cyclophosphamide followed by paclitaxel; Cohort B: 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel)
Number of subjects: 0
Study: 35681595

Group type: EXPERIMENTAL
Intervention: NIR fluorescence ARM procedure
Number of subjects: 109
Study: 35681678

Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Radical chemoradiotherapy (rCRT)
Number of subjects: 18
Study: 35683398

Group type: EXPERIMENTAL
Intervention: Home microsampling for quantification of adalimumab (ADM) concentrations using volumetric absorptive microsampling (VAMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lateral flow testing (LFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 0
Study: 35683419

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) with clinical score
Number of subjects: 393
Study: 35683423

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention by a geriatrician and a cardiologist
Number of subjects: 141

Group type: COMPARATOR
Intervention: Cardiologist alone (Control)
Number of subjects: 141
Study: 35683592

Group type: EXPERIMENTAL
Intervention: Cell therapy (intracoronary cell-based therapy)
Number of subjects: 1715

Group type: EXPERIMENTAL
Intervention: Cell therapy
Number of subjects: 1715
Study: 35684099

Group type: EXPERIMENTAL
Intervention: Amino acid-based formula (AAF) supplemented with 2'-fucosyllactose (2'-FL) and lacto-N-neotetraose (LNnT) for 4 months.
Number of subjects: 32
Study: 35684122

Group type: EXPERIMENTAL
Intervention: Adherence to Mediterranean diet (70.8% in group 1, highest quality of life)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Optimal levels of muscle strength
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Speed and agility
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Flexibility
Number of subjects: 305
Study: 35685496

Group type: EXPERIMENTAL
Intervention: NOACs
Number of subjects: 463

Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 463

Group type: COMPARATOR
Intervention: APT
Number of subjects: 463
Study: 35685504

Group type: EXPERIMENTAL
Intervention: Oral Anticoagulation (OAC) therapy
Number of subjects: 7698

Group type: COMPARATOR
Intervention: No Oral Anticoagulation (OAC) therapy
Number of subjects: 7698
Study: 35685868

Group type: EXPERIMENTAL
Intervention: SGA-LBW infants
Number of subjects: 8360
Study: 35685890

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed infant formula (HF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional formula (RF)
Number of subjects: 0
Study: 35686079

Group type: EXPERIMENTAL
Intervention: COVID+ patients
Number of subjects: 29

Group type: COMPARATOR
Intervention: COVID- controls
Number of subjects: 29
Study: 35686190

Group type: EXPERIMENTAL
Intervention: Active aiTBS stimulation while watching neutral videos
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Active aiTBS stimulation while watching smoking-related videos
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sham stimulation while watching smoking-related videos
Number of subjects: 89
Study: 35686441

Group type: EXPERIMENTAL
Intervention: High milk intake
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: High egg intake
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Poultry intake
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Multivariate models for predicting grade 1 to 3 CIAEs
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Multivariate models for predicting grade 2/3 CIAEs
Number of subjects: 130
Study: 35686551

Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35686702

Group type: EXPERIMENTAL
Intervention: alfapump® implantable device
Number of subjects: 106
Study: 35687173

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Ranibizumab (both dosages)
Number of subjects: 917
Study: 35687390

Group type: EXPERIMENTAL
Intervention: Unsupervised home exercises with visual feedback using the Valedo Home exergame, 9 sessions of 20 minutes over 3 weeks (T2-T3)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Unsupervised home exercises with visual feedback using the Valedo Home exergame
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 35687403

Group type: EXPERIMENTAL
Intervention: Internet-based interpersonal psychotherapy (IPT) modules with guided support
Number of subjects: 15
Study: 35687751

Group type: EXPERIMENTAL
Intervention: Virtual reality-mediated upper limb rehabilitation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Stretching and range-of-motion exercises
Number of subjects: 36
Study: 35687781

Group type: EXPERIMENTAL
Intervention: Triple guideline-based medical therapy (GBMT)
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Dual guideline-based medical therapy (GBMT)
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: Single guideline-based medical therapy (GBMT)
Number of subjects: 2680

Group type: COMPARATOR
Intervention: No guideline-based medical therapy (GBMT)
Number of subjects: 2680
Study: 35687896

Group type: EXPERIMENTAL
Intervention: Vestibular/Ocular Motor Screening for Concussion (VOMS)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Buffalo Concussion Bike Test (BCBT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: National Institutes of Health Toolbox-Cognition Battery (NIHTB-CB)
Number of subjects: 79